Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
03. Dezember 2024 08:30 ET
|
Eterna Therapeutics
Eterna Launches Research to Evaluate its Lead iMSC Therapy Candidate’s Ability to Induce and Modulate Antitumor Immunity in Ovarian and Breast Models
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
30. Oktober 2024 08:30 ET
|
Eterna Therapeutics
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
17. Oktober 2024 08:00 ET
|
Eterna Therapeutics
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license...
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
07. Oktober 2024 07:00 ET
|
Cybrexa Therapeutics
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
23. August 2024 16:30 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
14. August 2024 16:35 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
08. November 2023 07:30 ET
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.